Quick Answer
Semaglutide and tirzepatide are prescription medications for weight management and type 2 diabetes, most often given as a weekly injection. Semaglutide acts on one gut hormone receptor (GLP-1), while tirzepatide acts on two (GLP-1 and GIP). In a head-to-head trial, people taking tirzepatide lost more weight on average than people taking semaglutide. Their side effects are similar, and the better fit depends on your health history, goals, tolerance and access.
Who this is for: adults considering a GLP-1 medication for weight management, or those already taking one and wondering how the options compare
How Each Medication Works
Both medications copy the action of natural gut hormones released after you eat. Semaglutide mimics GLP-1, a hormone that helps signal fullness and helps the body release insulin when blood sugar rises.[1]
Tirzepatide acts on GLP-1 receptors and also on receptors for GIP, a second gut hormone involved in insulin release.[1] Researchers are still studying exactly how much the GIP action adds, but it is one reason the two drugs are not interchangeable.
Brand Names and How They Are Taken
Semaglutide is sold under brand names such as Wegovy (for weight management) and Ozempic (for type 2 diabetes), and it also comes in a daily pill form. Tirzepatide is sold as Zepbound (for weight management) and Mounjaro (for type 2 diabetes), and is currently given only as a weekly injection.[1]
With either injection, the dose starts low and is raised step by step over several weeks or months. The goal is the dose that works and that you tolerate well, which is not always the highest dose.
Steady habits like home-cooked meals support results on any weight-management medication.
What the Major Trials Found
The numbers below are averages from large studies of adults without diabetes. In every trial, medication was paired with diet and activity counseling.
- STEP 1: people taking semaglutide 2.4 mg weekly lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo.[2]
- SURMOUNT-1: people taking tirzepatide lost an average of 15% to 20.9% over 72 weeks, depending on dose, compared with 3.1% on placebo.[3]
- SURMOUNT-5: in the first head-to-head trial, 751 adults with obesity took the highest dose they could tolerate of either drug. After 72 weeks, average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide.[4]
Comparing separate trials is less reliable than a head-to-head study. And averages hide a wide range from person to person.
Side Effects and Safety
Because the two drugs work in similar ways, their side effects overlap. The most common are nausea, diarrhea, vomiting, constipation, belly pain and heartburn.[1] In SURMOUNT-5, 2.7% of people stopped tirzepatide because of digestive side effects, compared with 5.6% for semaglutide.[4]
Both carry an FDA boxed warning about thyroid C-cell tumors seen in animal studies. They are not used in people with a personal or family history of medullary thyroid cancer, and they are not recommended during pregnancy.[1] For more on what is common and when to call, see our guide to GLP-1 side effects.
Choosing Between Them
Greater average weight loss does not automatically make tirzepatide the right choice for everyone. Factors that may matter include:
- Other health conditions, such as type 2 diabetes, heart disease or sleep apnea, since approved uses differ
- How you have tolerated a GLP-1 medication in the past
- Medications you already take, especially insulin or other drugs that lower blood sugar
- Cost, insurance coverage and availability
Either works best alongside good nutrition, strength training and sleep. Weight often returns when either drug is stopped, so a long-term plan matters. Learn more about what happens when you stop a GLP-1 medication.
How We Approach GLP-1 Medications at Lake Forest Regenesis
Allana starts with an in-depth consultation and labs, reviewing your weight history, other health conditions, current medications and any past experience with GLP-1 medications. Together you weigh the expected benefits, side effects, dosing schedule and cost of semaglutide and tirzepatide. Follow-up visits are used to adjust the dose, manage side effects and track changes in body composition, not just the scale.
When to See a Provider
Seek emergency care or call 911 for severe belly pain that does not go away (especially if it spreads to your back), swelling of the face or throat, or trouble breathing. Get prompt care for vomiting that keeps you from holding down fluids, or yellowing of the skin or eyes. Book a visit if side effects make it hard to eat, you are thinking about switching medications, you are planning a pregnancy, or your progress has stalled.
Wondering whether semaglutide or tirzepatide fits you better? Allana can review your health history, goals and medications to help you choose with confidence.
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide?
Often, yes, with medical guidance. The new medication usually starts at a lower dose and is increased gradually, even if you were on a high dose of the other one.
Is tirzepatide always more effective?
Not for every person. Tirzepatide led to more weight loss on average in the head-to-head trial, but many people do very well on semaglutide, and tolerance and other health conditions matter too.
Are compounded versions the same as brand-name medications?
No. Compounded medications are not FDA-approved, which means the FDA does not review them for safety, effectiveness or quality before they are sold. When a compounded GLP-1 is prescribed at Lake Forest Regenesis, it comes from an FDA-registered compounding pharmacy.
Will I lose muscle on these medications?
Some of the weight lost on any GLP-1 medication can be muscle. Eating enough protein and doing regular strength training may help protect it.
References
- Cleveland Clinic. Tirzepatide vs. semaglutide. Read the article
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. Read the study
- American College of Cardiology. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) trial summary. Jastreboff AM, et al. N Engl J Med. 2022. Read the study
- American College of Cardiology. SURMOUNT-5: greater loss of weight, waist circumference with tirzepatide than semaglutide. Aronne LJ, et al. N Engl J Med. 2025. Read the study
This article is for general education and is not a substitute for individual medical advice. See our medical disclaimer.
